From Deals to Discovery Engines: How Big Pharma Is Redefining Early Drug Development
Pharmaceutical R&D is being reshaped by a wave of ecosystem-style partnerships and platform-driven collaborations across the biopharma industry, signaling a clear shift toward earlier, more integrated discovery strategies. At the same time, early functional validation is becoming a critical gatekeeper in preclinical decision-making, especially as new modalities increase the complexity of mechanism-of-action confirmation.
Behind these shifts is a broader redefinition of how confidence is built in drug candidates at the very beginning of development—where speed, biological relevance, and reproducibility increasingly determine downstream success.
2026-05-20
